LLY

Lilly’s rheumatoid arthritis drug using JAK inhibitors gets positive 2b results

Eli Lilly‘s (NYSE:LLY) rheumatoid arthritis treatment developed by drug developer Incyte (NASDAQ:INCY) using oral janus-associated kinases, or JAK, inhibitors, has produced positive phase 2b results, according to a company statement. The results were presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology. The randomized double-blind, placebo-controlled, dose-ranging study, known as JADA, involved […]

By Stephanie Baum

Pharma

Cardinal Health, Eli Lilly collaborate on Alzheimer’s imaging agent

Cardinal Health (NYSE:CAH) will manufacture and distribute a radioactive imaging agent from Eli Lilly (NYSE:LLY) that could help doctors diagnose Alzheimer’s disease. The imaging agent, called Amyvid, is scheduled for commercial launch on June 1, according to a statement from Dublin, Ohio-based Cardinal. Amyvid was approved by the U.S. Food and Drug Administration in April. […]

By Brandon Glenn

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Pharma

Physician satisfaction takes center of pharma’s new drug marketing practices

GlaxoSmithKline (NYSE:GSK) isn’t the only big drug company overhauling how pharmaceutical sales representatives talk to doctors. Others are now adapting with new sales practices. GlaxoSmithKline last year made waves when it implemented a new sales model that rewarded sales representatives for their knowledge of GSK drugs and their ability to communicate that knowledge to physicians. […]

By Frank Vinluan

Devices & Diagnostics

Medtronic and Eli Lilly join hands to combat Parkinson’s Disease

Medtronic (NYSE:MDT) and Eli Lilly (NYSE:LLY) announced Tuesday that the companies are collaborating to find a new treatment for Parkinson’s Disease. The partnership aims to research and develop a new approach to treating the debilitating disease. The new approach involves delivering a potential new medicine to the brain using an implantable drug delivery system, according to a […]

By Arundhati Parmar

Pharma

Veterinary products maker Aurora Pharmaceutical raising $5M

Two Northfield, Minnesota veterinarians, Mike Strobel and Mark Werner, are in the process of raising $5 million for their two-year-old Aurora Pharmaceutical as they seek to develop niche veterinary medicine products that will allow them compete with big pharmaceutical companies.

Pharma

Eli Lilly to pay up to $800M for Alzheimer’s tracing agent maker

Indianapolis drug maker Eli Lilly & Co. (NYSE:LLY) has agreed to pay up to $800 million for Avid Radiopharmaceuticals, the Philadelphia developer of a tracing agent that can help diagnose Alzheimer's disease. The tracing agent, florbetapir F 18 -- which last week topped the Cleveland Clinic's Top 10 Medical Innovations list for 2011 -- is coupled with a PET scan to allow doctors to see inside patients' brains to detect beta-amyloid plaques, the tell-tale signature of Alzheimer's.

By Mary Vanac